Cognate 3

Cognate 3 LLC is a biotechnology company based in Kirkland, Washington, that specializes in the development and intellectual property management of Salicinium, a proprietary glycobiotic compound. Salicinium is designed to selectively target the metabolic pathways of anaerobic cells, such as cancer cells and certain pathogens, by disrupting their fermentation-based energy production. The company's technology also aims to restore immune function by inhibiting the production of alpha-N-acetylgalactosaminidase (nagalase), an enzyme used by cancer cells to evade immune detection. Founded in 2008 by Joe Ernest Brown, Cognate 3 holds multiple patents related to the composition and therapeutic use of Salicinium. The company has supported extensive clinical studies involving hundreds of patients, positioning Salicinium as an adjunctive therapy for advanced-stage cancers and chronic infections. Cognate 3 has been involved in significant legal and clinical developments regarding the distribution and efficacy of its core technology.